Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda, Nab-paclitaxel, and Cisplatin Induction in HNSCC
NCT05272696Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Mar 2022
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Objective Response Rate at 24 months. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05272696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05272696.